Tesofensine

Structure: A phenyltropane derivative that inhibits the reuptake transporters for noradrenaline, dopamine and serotonin. It raises synaptic monoamine levels rather than acting as a direct receptor agonist, which is why it feels different from a classic stimulant like Clenbuterol despite an overlapping cardiovascular profile.

Dosage:

• 0.25mg once daily: the conservative starting point, and the dose with the mildest cardiovascular effect.
• 0.5mg once daily: the dose most commonly used, and the one with the best ratio of effect to tolerability in the Phase 2 data.
• 1mg once daily: produced the largest weight loss in trials, and also the largest heart rate and blood pressure increases along with the worst sleep and mood effects. Most people should not go here.
• Timing: morning, consistently. Dosing later meaningfully worsens insomnia.

Administration:

• Oral, once daily with or without food
• Do not titrate quickly. With a 9 day half-life you are still accumulating for over a month. A common mistake is deciding at day 5 that the dose is doing nothing and doubling it, then encountering the full effect of both doses two weeks later. Hold any dose for at least 3 to 4 weeks before judging it.
• Equally, stopping does not clear it quickly. If blood pressure or heart rate has climbed, expect a slow return over weeks, not days.

Key Notes:

• The efficacy data is real and it is Phase 2. The 24 week TIPO-1 trial in obese patients showed placebo-subtracted weight loss of roughly 4.5%, 9.2% and 10.6% at 0.25mg, 0.5mg and 1mg respectively, alongside diet. That is genuinely competitive with early GLP-1 results. What it does not have is Phase 3 confirmation or a long-term cardiovascular outcomes trial.
• The cardiovascular effects are the reason it stalled. Heart rate rose in a dose-dependent way (in the range of 7 to 8 bpm at the top dose) with accompanying blood pressure increases. On a platform that tracks blood pressure and resting heart rate, this is not an abstract concern; it is the thing you will watch it do to your own numbers.
• The response to that problem was Tesomet, a fixed combination of tesofensine with the beta blocker metoprolol, developed to blunt the cardiovascular effect while retaining the weight loss. That programme targeted hypothalamic obesity and Prader-Willi syndrome rather than general obesity. Its existence is a straightforward admission that tesofensine alone has a cardiovascular problem.
• Drug interactions are the sharpest practical risk. Do not combine with MAOIs. Combining with SSRIs, SNRIs or other serotonergic agents raises serotonin syndrome risk. Stacking on top of other stimulants (clenbuterol, high-dose ephedrine, yohimbine, or a heavy pre-workout) compounds the cardiovascular load in a way that is genuinely dangerous rather than just uncomfortable.
• Mood and sleep effects deserve respect. Dopaminergic and noradrenergic agents in a dieting, energy-depleted athlete can produce irritability, anxiety and insomnia that the person attributes to the diet. If you already have a psychiatric history, this is not a good fit.
• Compared with the GLP-1 route: Semaglutide, Tirzepatide and Retatrutide achieve comparable or better weight loss with GI side effects instead of cardiovascular ones, and with far more human data behind them. Tesofensine's honest niche is people who cannot tolerate GLP-1 nausea, not people looking for something stronger.
• It has never been approved in the US, EU, UK or Australia. Everything available online is unapproved material of unverified identity and dose, and dose accuracy matters more than usual when the therapeutic window sits between 0.25mg and 1mg.

Bloodwork Monitoring:

• Systolic BP and Diastolic BP: the primary monitoring target. Take a baseline over several days before starting, then track weekly. A sustained rise of more than 5-10mmHg, or any reading crossing into stage 2 territory, means reduce or stop.
• Resting Heart Rate: measure first thing in the morning before caffeine. Because of the long half-life the climb is gradual, and it is easy to normalise a 10 bpm drift if you are not logging it.
• Body Weight: track weekly rather than daily, and pair it with waist measurements so you can see whether you are losing fat or just losing.
• Potassium and Sodium: not affected by tesofensine directly, but worth checking if you are stacking it with clenbuterol or dieting aggressively.
• Glucose and HbA1c: both usually improve with the weight loss. Useful for confirming the loss is metabolically meaningful.
• ALT, AST and a lipid panel: standard 12 week follow-up, mostly to capture the benefit of the weight loss rather than any drug effect.